Outcome of COVID-19 in Patients with Myasthenia May Not Only Depend on the Immunologic Disease

Josef Finsterer, MD, PhD; Carla A. Scorza; Fulvio A. Scorza, MD; Ana C Fiorini, MD

doi:10.47310/iarjmsr.2020.V01i02.04

Outcome of COVID-19 in Patients with Myasthenia May Not Only Depend on the Immunologic Disease

Authors

Josef Finsterer, MD, PhD Klinik Landstrasse, Messerli Institute, Vienna, Austria
Carla A. Scorza Disciplina de Neurociência, Escola Paulista de Medicina/Universidade Federal de Sao Paulo/. (EPM/UNIFESP). Sao Paulo, Brasil
Fulvio A. Scorza, MD Disciplina de Neurociência, Escola Paulista de Medicina/Universidade Federal de Sao Paulo/. (EPM/UNIFESP). Sao Paulo, Brasil
Ana C Fiorini, MD Programa de Estudos Pos-Graduado em Fonoaudiologia, Pontifícia Universidade Catolica de Sao Paulo (PUC-SP). Departamento de Fonoaudiologia. Escola Paulista de Medicina/Universidade Federal de Sao Paulo (EPM/UNIFESP). Sao Paulo, Brasil

DOI:

https://doi.org/10.47310/iarjmsr.2020.V01i02.04

Keywords:

myasthenia, COVID-19, SARS-CoV-2, neuromuscular transmission.

Abstract

With interest we read the article by Camelo-Filho et al., (2020) about 15 patients with myasthenia gravis (MG) admitted to four hospitals in Sao Paolo because of an infection with SARS-CoV-2 (COVID-19). The authors found that most MG patients developed a severe course of COVID-19, such that 87% of the MG patients required transfer to the intensive care unit (ICU), that 73% required artificial ventilation, and that 30% of these patients died. We have the following comments and concerns.

Downloads

Published

2020-10-30

How to Cite

Josef Finsterer, MD, PhD, Carla A. Scorza, Fulvio A. Scorza, MD, & Ana C Fiorini, MD. (2020). Outcome of COVID-19 in Patients with Myasthenia May Not Only Depend on the Immunologic Disease. IAR Journal of Medicine and Surgery Research, 1(2), 11–12. https://doi.org/10.47310/iarjmsr.2020.V01i02.04